Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel
NYSEAMERICAN:AIM

AIM ImmunoTech Q4 2025 Earnings Report

AIM ImmunoTech logo
$0.31 -0.04 (-12.18%)
Closing price 06/26/2026 04:10 PM Eastern
Extended Trading
$0.31 0.00 (-0.03%)
As of 06/26/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

AIM ImmunoTech EPS Results

Actual EPS
-$0.45
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

AIM ImmunoTech Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AIM ImmunoTech Announcement Details

Quarter
Q4 2025
Date
3/27/2026
Time
After Market Closes
Conference Call Date
Tuesday, March 31, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

AIM ImmunoTech's Q4 2025 Annual reportAnnual report
(10-K)

AIM ImmunoTech Earnings Headlines

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316820/29489/en/aim-immunotech-accelerates-toward-potential-pivotal-pancreatic-cancer-program-as-ampligen-continues-to-advance-through-key-clinical-milestones.html
AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences
June 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260623153580/en/aim-sports-group%e2%80%99s-national-socal-cup-%e2%80%98the-showcase%e2%80%99-event-serves-up-a-weekend-of-new-experiences/
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
June 28 at 1:00 AM  |  Chaikin Analytics (Ad)
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315298/29489/en/aim-immunotech-to-present-in-the-webull-corporate-connect-webinar-series.html
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/18/3314251/29489/en/aim-immunotech-achieves-clinical-milestone-as-final-subject-receives-first-dose-in-phase-2-duripanc-study-in-metastatic-pancreatic-cancer.html
AIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay Area
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313210/0/en/aim-talks-china-2026-convenes-in-guangzhou-advancing-strategic-partnerships-and-cross-border-investment-across-the-greater-bay-area.html
See More AIM ImmunoTech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AIM ImmunoTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AIM ImmunoTech and other key companies, straight to your email.

About AIM ImmunoTech

AIM ImmunoTech (NYSEAMERICAN:AIM) is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats. AIM ImmunoTech has collaborated with government agencies and academic institutions to support its clinical development, leveraging these partnerships to access specialized expertise and streamline regulatory pathways.

Headquartered in Ocala, Florida, AIM ImmunoTech conducts its research and manufacturing operations in the United States, while seeking to establish strategic collaborations that extend its global reach. The company’s management team comprises experienced professionals in biotechnology development, regulatory affairs and commercial strategy, with a shared commitment to bringing novel immunotherapeutic solutions to market.

View AIM ImmunoTech Profile
Earnings Tools